Fundraising Fox
/Companies
Sign in

Oncusp Therapeutics

New York, US · Founded 2021 · 29 employees on LinkedIn · 7 known investors

Find your way into Oncusp Therapeutics

Sign up to see every warm intro you have to Oncusp Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Oncusp Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.

BiotechMedical Devices

Founders & leadership

DB
Dr. Bing YuanCo-Founder, Chief Executive Officer
DE
Dr. Eric SlosbergCo-Founder, Chief Development Officer
DA
Dr. Andy FuCo-Founder, Chief Business Officer
BY
Bing Yuan, Ph.D., MBACo-Founder, Chief Executive Officer
ES
Eric Slosberg, Ph.D.Co-Founder, Chief Development Officer
AF
Andy Fu, PharmD, MBACo-Founder, Chief Business Officer

Investors · 7

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

De Novo VenturesreportedBoston

How we know: a partner's Signal profile · Not right? Tell us

Insight PartnersreportedNew York · $120M – $350M

How we know: funding news feeds · Not right? Tell us

NVIDIAreportedSanta Clara

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 2

OncosenxOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies working in the same space as Oncusp Therapeutics.

Frequently asked questions

What does Oncusp Therapeutics do?
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Who founded Oncusp Therapeutics?
Oncusp Therapeutics was founded by Dr. Bing Yuan, Dr. Eric Slosberg, Dr. Andy Fu, Bing Yuan, Ph.D., MBA, Eric Slosberg, Ph.D., Andy Fu, PharmD, MBA in 2021.
Who are Oncusp Therapeutics's investors?
Oncusp Therapeutics's investors include OrbiMed, Catalio Capital Management, LP, F-Prime Capital, Sofinnova Ventures, De Novo Ventures, Insight Partners, NVIDIA.
Where is Oncusp Therapeutics headquartered?
Oncusp Therapeutics is headquartered in New York, US.